ID

21437

Description

Acute Promyelocytic Leukemia 2006 (APL); ODM derived from: https://clinicaltrials.gov/show/NCT00378365

Lien

https://clinicaltrials.gov/show/NCT00378365

Mots-clés

  1. 21/04/2017 21/04/2017 -
  2. 21/04/2017 21/04/2017 -
Téléchargé le

21 avril 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Leukemia, Promyelocytic, Acute NCT00378365

Eligibility Leukemia, Promyelocytic, Acute NCT00378365

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of apl based on morphological grounds, which will have to be confirmed by the presence of t(15;17) and/or pml-rara rearrangement with characterization of the bcr subtype (pml-rar characterization).
Description

Acute Promyelocytic Leukemia | t(15;17)(q22;q12) | t(15;17)(PML,RARA) | PML-RARa bcr1 fusion protein, human

Type de données

boolean

Alias
UMLS CUI [1]
C0023487
UMLS CUI [2]
C1515724
UMLS CUI [3]
C1979990
UMLS CUI [4]
C3493223
untreated patients.
Description

Patients Untreated

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0332155
no contraindication to intensive chemotherapy (especially well documented cardiac contraindication to idarubicin).
Description

ID.3

Type de données

boolean

in female patients: absence of pregnancy and adequate contraceptive methods (due to teratogenetic effects of atra in early pregnancy).
Description

ID.4

Type de données

boolean

absence of hypersensitivity to arsenic derivatives.
Description

Arsenic AND/OR arsenic compound Hypersensitivity Absent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0300979
UMLS CUI [1,2]
C0020517
UMLS CUI [1,3]
C0332197
no qt interval prolongation or complete atria-ventricular block.
Description

ID.6

Type de données

boolean

written informed consent.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients already treated.
Description

Patients Treated

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1522326
patients with contraindication to intensive chemotherapy, especially well documented cardiac contraindication to idarubicin.
Description

ID.9

Type de données

boolean

in female patients: pregnancy or absence of adequate contraceptive methods
Description

ID.10

Type de données

boolean

qt interval prolongation or complete atria-ventricular block.
Description

ID.11

Type de données

boolean

hypersensitivity to arsenic derivatives.
Description

Hypersensitivity Arsenic AND/OR arsenic compound

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0300979

Similar models

Eligibility Leukemia, Promyelocytic, Acute NCT00378365

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Acute Promyelocytic Leukemia | t(15;17)(q22;q12) | t(15;17)(PML,RARA) | PML-RARa bcr1 fusion protein, human
Item
diagnosis of apl based on morphological grounds, which will have to be confirmed by the presence of t(15;17) and/or pml-rara rearrangement with characterization of the bcr subtype (pml-rar characterization).
boolean
C0023487 (UMLS CUI [1])
C1515724 (UMLS CUI [2])
C1979990 (UMLS CUI [3])
C3493223 (UMLS CUI [4])
Patients Untreated
Item
untreated patients.
boolean
C0030705 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
ID.3
Item
no contraindication to intensive chemotherapy (especially well documented cardiac contraindication to idarubicin).
boolean
ID.4
Item
in female patients: absence of pregnancy and adequate contraceptive methods (due to teratogenetic effects of atra in early pregnancy).
boolean
Arsenic AND/OR arsenic compound Hypersensitivity Absent
Item
absence of hypersensitivity to arsenic derivatives.
boolean
C0300979 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
ID.6
Item
no qt interval prolongation or complete atria-ventricular block.
boolean
Informed Consent
Item
written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Patients Treated
Item
patients already treated.
boolean
C0030705 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
ID.9
Item
patients with contraindication to intensive chemotherapy, especially well documented cardiac contraindication to idarubicin.
boolean
ID.10
Item
in female patients: pregnancy or absence of adequate contraceptive methods
boolean
ID.11
Item
qt interval prolongation or complete atria-ventricular block.
boolean
Hypersensitivity Arsenic AND/OR arsenic compound
Item
hypersensitivity to arsenic derivatives.
boolean
C0020517 (UMLS CUI [1,1])
C0300979 (UMLS CUI [1,2])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial